Table 2.
Summary of results of clinical trials of decitabine in MDS
CMML indicates chronic myelomonocytic leukemia; ND, not described; PR, partial remission; HI, hematologic improvement; ORR, overall response rate (CR + PR + HI); and Cyto, cytogenetic response.
*Dysplasia possible.
†IWG 2000 criteria.
